Our new report on the role of the U.S. government in supporting product development for global health
Despite recent progress in global health, poor populations in low- and middle-income countries continue to suffer and die disproportionately from poverty related and neglected diseases (PRNDs). For many of these diseases, new medicines, vaccines, and diagnostic tests are urgently needed. However, the lack of market incentives is a major barrier to research and development (R&D) for such health technologies. Governments and philanthropic foundations have helped to address this gap by funding product development for PRNDs. In a new study that we published yesterday, we focused on one important government funder of such product development: the United States government. Our study, called “Strengthening the United States Government’s Role in Product Development for Global Health,” conducted in collaboration with other colleagues in the Duke Global Health Institute and at the Duke Margolis…